Premium
Berberine: A novel therapeutic strategy for cancer
Author(s) -
Samadi Parisa,
Sarvarian Parisa,
Gholipour Elham,
Asenjan Karim Shams,
AghebatiMaleki Leili,
Motavalli Roza,
HojjatFarsangi Mohammad,
Yousefi Mehdi
Publication year - 2020
Publication title -
iubmb life
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.132
H-Index - 113
eISSN - 1521-6551
pISSN - 1521-6543
DOI - 10.1002/iub.2350
Subject(s) - berberine , berberis , phytochemical , nutraceutical , autophagy , traditional medicine , cancer , cell cycle checkpoint , apoptosis , pharmacology , cell cycle , biology , antiparasitic , medicine , biochemistry , pathology
Cancer, even currently, is one of the main reasons for mortality and morbidity, worldwide. In recent years, a great deal of effort has been made to find efficient therapeutic strategies for cancer, however, particularly with regards to side effects and the possibility of complete remission. Berberine (BBR) is a nature‐driven phytochemical component originated from different plant groups such as Berberis vulgaris , Berberis aquifolium , and Berberis aristata. BBR is a well‐known nutraceutical because of its wide range of pharmacological activities including anti‐inflammatory, antidiabetic, antibacterial, antiparasitic, antidiarrheal, antihypertensive, hypolipidemic, and fungicide. In addition, it exhibits inhibitory effects on multiple types of cancers. In this review, we have elaborated on the anticancer effects of BBR through the regulation of different molecular pathways such as: inducing apoptosis, autophagy, arresting cell cycle, and inhibiting metastasis and invasion.